PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9073310-5	1997	VX-710 was approximately 2-fold more effective than verapamil, MS-209 and CsA in modulating MRP-mediated multidrug resistance, whereas GF120918 had no significant effect.	dofequidar	63-69	ATP binding cassette subfamily C member 1	Homo sapiens	92-95
12002701-12	2002	This study demonstrated that MS-209 increases the 99mTc-MIBI accumulation in Pgp-positive tumours.	dofequidar	29-35	phosphoglycolate phosphatase	Mus musculus	77-80
11197207-9	2000	The addition of MS-209 in vitro as an MDR-reversing agent significantly enhanced the intracellular daunorubicin/Rhodamine 123 accumulation and the retention of P-gp+ leukemic blast cells to a level similar to that of P-gp- blast cells.	dofequidar	16-22	ATP binding cassette subfamily B member 1	Homo sapiens	160-164
11197207-9	2000	The addition of MS-209 in vitro as an MDR-reversing agent significantly enhanced the intracellular daunorubicin/Rhodamine 123 accumulation and the retention of P-gp+ leukemic blast cells to a level similar to that of P-gp- blast cells.	dofequidar	16-22	ATP binding cassette subfamily B member 1	Homo sapiens	217-221
10049760-4	1999	In multi-drug-resistant MKN45R0.8 cells selected by doxorubicin, MS-209 dose dependently reduced MRP-mediated [3H]leukotriene C4 uptake and increased calcein accumulation.	dofequidar	65-71	ATP binding cassette subfamily C member 1	Homo sapiens	97-100
9788575-6	1998	MS-209 restored ADM incorporation and this effect was enhanced by CsA and VER, suggesting that these synergistic effects were due to competitive inhibition of P-gp function.	dofequidar	0-6	ATP binding cassette subfamily B member 1	Homo sapiens	159-163
7828268-8	1995	MS-209 also enhanced the chemotherapeutic effect of ADM in P388/ADM-bearing mice.	dofequidar	0-6	adrenomedullin	Mus musculus	52-55
7634376-1	1995	MS-209 is a novel quinoline compound which can overcome multidrug resistance (MDR) both in vitro and in vivo, while having a low level of side effects, and is now being evaluated in a clinical phase II study.	dofequidar	0-6	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	78-81
7828268-8	1995	MS-209 also enhanced the chemotherapeutic effect of ADM in P388/ADM-bearing mice.	dofequidar	0-6	adrenomedullin	Mus musculus	59-67
7828268-11	1995	Furthermore, the accumulation of ADM in K562/ADM cells was increased more efficiently by MS-209 than by verapamil.	dofequidar	89-95	adrenomedullin	Mus musculus	33-36
7828268-11	1995	Furthermore, the accumulation of ADM in K562/ADM cells was increased more efficiently by MS-209 than by verapamil.	dofequidar	89-95	adrenomedullin	Mus musculus	45-48
19673889-0	2009	Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.	dofequidar	0-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	110-115
19673889-0	2009	Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.	dofequidar	0-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	116-120
19673889-4	2009	Dofequidar fumarate, an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both.	dofequidar	0-19	ATP binding cassette subfamily B member 1	Homo sapiens	106-111
19673889-4	2009	Dofequidar fumarate, an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both.	dofequidar	0-19	phosphoglycolate phosphatase	Homo sapiens	112-116
19673889-4	2009	Dofequidar fumarate, an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both.	dofequidar	0-19	ATP binding cassette subfamily C member 1	Homo sapiens	118-123
19673889-9	2009	The in vitro vesicle transporter assay clarified that dofequidar had the ability to suppress ABCG2/BCRP function.	dofequidar	54-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	93-98
19673889-9	2009	The in vitro vesicle transporter assay clarified that dofequidar had the ability to suppress ABCG2/BCRP function.	dofequidar	54-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	99-103